Antigen Binding Specificity Metric via Beta Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing antigen binding specificity of antigen binding molecules are time-consuming and resource-intensive, particularly when evaluating at a single cell resolution.
Innovation Solution
A system and method for determining antigen binding specificity by calculating a specificity metric based on measurements of target antigen and control binding to antigen binding molecules, using a cumulative distribution function of a beta distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to assess antigen binding specificity at single cell resolution, then measurement precision is improved, but productivity deteriorates due to time-consuming and resource-intensive processes
Solution Approach 1:
The patent transforms the specificity assessment from a traditional binary classification (binding vs non-binding) to a continuous probabilistic parameter using beta distribution. By modeling the binding specificity as a continuous variable with associated uncertainty, the system can process multiple cells simultaneously while maintaining precision through probabilistic metrics rather than requiring exhaustive traditional analysis of each cell individually
Solution Approach 2:
The patent creates a computational model that replicates and generalizes findings from a subset of cells to the entire population. By using beta distribution parameters estimated from measured cells, the system infers specificity metrics for all cells without performing exhaustive traditional assays on each one, thereby scaling throughput while maintaining measurement precision
2Reliability
If traditional methods are used to identify antigen binding molecules, then reliability is improved, but loss of time increases due to time-consuming processes
Solution Approach 1:
The patent performs preliminary computational preparation by establishing beta distribution models and specificity thresholds before actual cell analysis. These pre-computed reference frameworks enable rapid assessment of new cells without requiring time-consuming traditional methods for each evaluation, thus reducing overall assessment time while maintaining identification accuracy
Solution Approach 2:
The patent replaces traditional mechanical/experimental verification methods with computational probabilistic modeling. Instead of relying on time-consuming experimental validation for each cell, the system uses beta distribution-based computational algorithms to rapidly assess specificity, substituting physical measurement processes with efficient mathematical calculations that maintain reliability
3Measurement precision
If comprehensive assessment of antigen binding molecules is performed, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent extracts the essential complexity from comprehensive cell-by-cell analysis and concentrates it into a single beta distribution model framework. By taking out the core probabilistic modeling logic and separating it from the data processing pipeline, the system achieves high measurement precision through a unified mathematical approach rather than through complex multi-step computational procedures
Data Source
AI summary
Described herein are methods and related systems and computer program products for assessing the antigen binding specificity of an antigen binding molecule (ABM) expressed by one or more immune cells and may include contacting a plurality of cells comprising at least one antigen binding molecule with a first target antigen and a control; determining a first readout based on the binding of the at least one antigen binding molecule to the first target antigen; determining a second readout based on the binding of the at least one antigen binding molecule to the control; and determining, from the first readout and the second readout, a specificity metric representing the specificity of the at least one antigen binding molecule binding to the target antigen relative to the control.


